SGLT2 inhibitors in heart failure: insights from plasma proteomics

Eur Heart J. 2022 Dec 21;43(48):5003-5005. doi: 10.1093/eurheartj/ehac624.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Glucosides
  • Heart Failure* / drug therapy
  • Humans
  • Proteomics
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin
  • Glucosides